Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

A group of vaccine-skeptical doctors and mandate opponents is challenging the CDC’s childhood immunization schedule in ...

Viking Therapeutics stock plunges 37% as trial data sparks concerns over dropout rates and side effects despite weight loss ...

In a groundbreaking development, Novo Nordisk's Wegovy has received U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver ...

Discover how weight-loss drugs like Wegovy and Mounjaro are being tested for a range of health conditions including alcohol addiction, Alzheimer's disease, and cardiovascular issues. Learn about their ...

This episode of Pharma Pulse covers Novo Nordisk’s FDA win for Wegovy in MASH-related liver fibrosis, new research on a ...

Novo said cash-paying Americans can now buy Ozempic for $499 per month through various channels including its official ...

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach ...

In a groundbreaking development, Novo Nordisk's Wegovy has received U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver ...

The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

Novo Nordisk stock rallies as the Danish pharma giant makes two big announcements. TD Cowen analysts recommend buying NVO ...